"There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person's daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time."
A new patient-reported outcome instrument was developed to assess daytime functioning in patients with insomnia and Idorsia included it in daridorexant's Phase 3 program.
Jazz Pharmaceuticals plc announced that the first patient has been enrolled in a Phase 3 clinical study evaluating JZP-258, an investigational oxybate product candidate with 90% less sodium content than Xyrem (sodium oxybate)...
The sale of the sterile injectable drug portfolio is a significant milestone for the company, as it reflects a commitment to strategically focus on advancing FT218.
Read More
Researchers demonstrated that the neurotransmitter serotonin plays a critical role in rousing the brain from sleep when CO2 levels rise.
Read More
An investigational CPAP alternative that uses tetanus toxin molecules to potentially treat sleep-disordered breathing is being unveiled at a global biotech innovation event this week.
Read MoreIts findings suggest that ZTL-101 cannabis treatment is safe and effective for chronic insomnia.
Read MoreTherapix Biosciences has closed a joint venture transaction for collaboration in the field of developing pharmaceuticals for a sleep-related indication.
Read MoreTokyo-based Sosei Group Corp has made further progress with its orexin program, which is being developed in conjunction with its spin-off companies Orexia Ltd and Inexia Ltd.
Read MoreRespireRx Pharmaceuticals Inc, which is developing dronabinol for the treatment of obstructive sleep apnea, announces that Timothy Jones has joined as its president and CEO.
Read MoreIdorsia Ltd reports positive top-line results of the first pivotal Phase 3 study investigating 25 and 50 mg doses of its dual orexin receptor antagonist, daridorexant, in 930 adult and elderly patients with insomnia.
Read More
The disorder has several different causes, researchers are learning. That finding opens the door for personalized therapies—and perhaps even effective drugs.
Read MoreAvadel Pharmaceuticals plc announced positive topline data from its pivotal Phase 3 REST-ON trial assessing the safety and efficacy of FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Read More
The FDA accepted for filing with Priority Review the Jazz Pharmaceuticals plc’s NDA seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read MoreAvadel Pharmaceuticals plc has completed the REST-ON Phase 3 clinical trial for FT218. The company expects to announce topline data from the study in the second quarter of 2020.
Read MoreSouth Australians with obstructive sleep apnea are invited to take part in a clinical trial to develop the first ever medication to treat the sleep disorder.
Read More
Zelira Therapeutics Ltd reported positive Phase 1b/2a results confirming that ZLT-101 therapy achieved the primary endpoint of a statistically significant improvement in Insomnia Severity Index (ISI) scores in patients diagnosed with chronic insomnia.
Read More